Phase 1 start of treatment for Geographic Atrophy patients
Boehringer initiates Phase 1 evaluation of BI 771716 a treatment for preserving vision of people living with geographic atrophy (GA)
Search
Phase 3 studies survodutide obesity and overweight
Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Interstitial lung disease in rheumatoid arthritis (RA-ILD)
Interstitial lung disease (ILD) is the most common type of lung condition associated with the systemic autoimmune disease rheumatoid arthritis (RA).
Boehringer Ingelheim half-year results 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Partnering with Lifebit to detect global disease outbreaks
Boehringer Ingelheim partners with Lifebit to detect global infectious disease outbreaks
Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases
Diabetic Retinopathy
Diabetic retinopathy affects 1 in 3 people with diabetes and is the leading cause of vision loss in adults of working age.
Connect the Docs
Experts discuss interconnectivitiy of heart failure, diabetes, and kidney disease and the importance of early diagnosis.
FDA approves Jardiance treatment chronic kidney disease
U.S. FDA approves Jardiance® for treatment of adults with chronic kidney disease
Facts About IPF
IPF is a debilitating and fatal lung disease.
Chronic kidney disease in cats
Detect and manage chronic kidney disease and high blood pressure in cats
Retinal health
Partnering_in_Retinal Health
cardiometabolic_retinal_partner_interests.pdf
Retinal_Health.pdf
PC-CRP-102092 Retinal Health Wet AMD infographic.pdf
Retinal_Health_geographic_atrophy_infographic.pdf
Retinal_Health_DR infographic.pdf
BI_Retinal_WetAMD_infographic.pdf
Retinal_Health_Flyer_BIO-2021_bis-2021-08-03.pdf
Partnering Interests in Retinal Health
partnering-retinal-health-may-2023-corp.pdf
Partnering in Retinal Health HP OCTOBER 2024 CORP_1.pdf
Positive results Diabetic Macular Ischemia treatment
HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment
Improving lives by providing better access to treatments
Our ‘Access to Healthcare’ initiative aims to extend support to underserved communities affected by Non-Communicable Diseases